Debrisoquine metabolism and genetic predisposition to lung cancer | Zendy

MR Law | Zendy; M Hetzel | Zendy; JR Idel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Debrisoquine metabolism and genetic predisposition to lung cancer

Author(s) -

MR Law,

M Hetzel,

JR Idel

Publication year - 1989

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1989.142

Subject(s) - debrisoquine , genetic predisposition , lung cancer , cancer , medicine , bioinformatics , biology , genetics , oncology , metabolism , cancer research , disease , cyp2d6 , cytochrome p450

It is usually the metabolites of environmental carcinogens that initiate a cancer (Miller & Miller, 1983), and if the metabolism were subject to genetically determined polymorphism, there could be variation between smokers in their susceptibility to smoking-related lung cancer. We report a case-control study using the drug debrisoquine as a potential marker of such genetically determined susceptibility to lung

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research